Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Lipocine Inc
LPCNCurrent price
3.19 USD
+0.01 USD (+0.31%)
Last closed
3.10 USD
Company
www.lipocine.com
ISIN
US53630X1046
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
17 014 146 USD
Yield for 12 month
-32.56 %
1Y
3Y
5Y
10Y
15Y
LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. Address: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.75 USDP/E ratio
–Dividend Yield
–Current Year
+11 198 144 USD
Last Year
-2 850 818 USD
Current Quarter
+3 491 406 USD
Last Quarter
–
Current Year
+11 198 144 USD
Last Year
-2 850 818 USD
Current Quarter
+3 491 406 USD
Last Quarter
–
Key Figures LPCN
1 year
3 years
5 years
10 years
EBITDA
-1 113 929 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-3.17 %
PEG Ratio
–
Return On Equity TTM
0.040 %
Wall Street Target Price
6.75 USD
Revenue TTM
11 198 144 USD
Book Value
3.93 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
1 515.00 %
Dividend Yield
–
Gross Profit TTM
11 198 144 USD
Earnings per share
–
Diluted Eps TTM
–
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
0.080 %
Dividend Analytics LPCN
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History LPCN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:17
Payout Ratio TTM
–
Last Split Date
12.05.2023
Stock Valuation LPCN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.62
Price Sales TTM
1.52
Enterprise Value EBITDA
0.65
Price Book MRQ
0.81
Financials LPCN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators LPCN
For 52 weeks
2.75 USD
11.79 USD
50 Day MA
3.27 USD
Shares Short Prior Month
82 750
200 Day MA
4.47 USD
Short Ratio
6.29
Shares Short
76 442
Short Percent
1.47 %
BeatStart